Showing 1 - 6 results of 6 for search 'Christopher J. Bruno', query time: 0.03s Refine Results
  1. 1
    Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis

    Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis by Emmanuel Roilides, John S. Bradley, Julia Lonchar, Jennifer A. Huntington, Prachi Wickremasingha, Feng-Hsiu Su, Christopher J. Bruno, Matthew G. Johnson

    Published 2023-10-01
    Get full text
    Article
  2. 2
    Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem

    Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, contro... by Marin H. Kollef, Jean-François Timsit, Ignacio Martin-Loeches, Richard G. Wunderink, Jennifer A. Huntington, Erin H. Jensen, Brian Yu, Christopher J. Bruno

    Published 2022-12-01
    Get full text
    Article
  3. 3
    Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

    Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized,... by Ignacio Martin-Loeches, Andrew F. Shorr, Richard G. Wunderink, Marin H. Kollef, Jean-François Timsit, Brian Yu, Jennifer A. Huntington, Erin Jensen, Christopher J. Bruno

    Published 2023-02-01
    Get full text
    Article
  4. 4
    A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections

    A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese parti... by Yihong Sun, Jia Fan, Gang Chen, Xiaofei Chen, Xiaoling Du, Ye Wang, Hui Wang, Fang Sun, Matthew G. Johnson, Mekki Bensaci, Jennifer A. Huntington, Christopher J. Bruno

    Published 2022-10-01
    Get full text
    Article
  5. 5
    Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

    Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial by Andrew F. Shorr, Christopher J. Bruno, Zufei Zhang, Erin Jensen, Wei Gao, Hwa-Ping Feng, Jennifer A. Huntington, Brian Yu, Elizabeth G. Rhee, Carisa De Anda, Sumit Basu, Marin H. Kollef

    Published 2021-10-01
    Get full text
    Article
  6. 6
    Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

    Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial by Jean-François Timsit, Jennifer A. Huntington, Richard G. Wunderink, Nobuaki Shime, Marin H. Kollef, Ülo Kivistik, Martin Nováček, Álvaro Réa-Neto, Ignacio Martin-Loeches, Brian Yu, Erin H. Jensen, Joan R. Butterton, Dominik J. Wolf, Elizabeth G. Rhee, Christopher J. Bruno

    Published 2021-08-01
    Get full text
    Article

Search Tools: